Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $2.8 million.

  • Myriad Genetics' Capital Expenditures fell 20.00% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year decrease of 42.91%. This contributed to the annual value of $19.0 million for FY2024, which is 69.94% down from last year.
  • Myriad Genetics' Capital Expenditures amounted to $2.8 million in Q3 2025, which was down 0.00% from $2.8 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Capital Expenditures high stood at $23.5 million for Q1 2023, and its period low was $2.8 million during Q2 2025.
  • Its 3-year average for Capital Expenditures is $8.5 million, with a median of $5.3 million in 2025.
  • As far as peak fluctuations go, Myriad Genetics' Capital Expenditures skyrocketed by 490.00% in 2022, and later crashed by 72.34% in 2024.
  • Over the past 5 years, Myriad Genetics' Capital Expenditures (Quarterly) stood at $3.4 million in 2021, then skyrocketed by 329.41% to $14.6 million in 2022, then slumped by 31.51% to $10.0 million in 2023, then tumbled by 64.00% to $3.6 million in 2024, then decreased by 20.00% to $2.8 million in 2025.
  • Its Capital Expenditures was $2.8 million in Q3 2025, compared to $2.8 million in Q2 2025 and $5.3 million in Q1 2025.